Brand Name

Vfend

Generic Name
Voriconazole
View Brand Information
FDA approval date: May 24, 2002
Classification: Azole Antifungal
Form: Injection, Tablet, Powder, Suspension

What is Vfend (Voriconazole)?

VFEND is an azole antifungal indicated for the treatment of adults and pediatric patients 2 years of age and older with: Invasive aspergillosis.

Approved To Treat

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

A Multicenter, Prospective, Randomized Controlled Study of the Standard 3+7 Regimen Versus Venetoclax Combined With CACAG Regimen in Newly Diagnosed Adult Patients With Intermediate- and High-risk Acute Myeloid Leukemia

Summary: The purpose of this study is to compare the efficacy and safety of venetoclax combined with the CACAG regimen with the traditional 3+7 regimen in the treatment of newly diagnosed intermediate- or high-risk acute myeloid leukemia (AML).

Phase 1B/2A Study of Weekly Decitabine and Venetoclax Treatment as Maintenance Therapy in High-Risk Myeloid Malignancy Patients Post Allograft Stem Cell Transplant

Summary: The goal of this interventional clinical trial is to determine if low doses of gentle chemotherapy after bone marrow transplant may prevent relapse and promote an increase in survival and decrease in side effects in participants with acute myeloid leukemia and myelodysplastic syndromes. The main question it aims to answer is whether or not providing a new, gentler way of administering chemotherapy...